LAS VEGAS — Samsung Biologics CEO John Rim attended CES 2026 last week to explore strategies for artificial intelligence (AI)-driven digital transformation in manufacturing. “Attending CES allows us to experience global trends in advanced technologies and gain insights for manufacturing innovation in the AI era,” Rim said. He also participated in various sessions during CES, including Caterpillar’s keynote, discussions on AI adoption in manufacturing and automation-based smart factory technologi
The biopharmaceutical manufacturing sector will likely see increased adoption of AI-driven solutions to improve efficiency, reduce manufacturing costs, and enhance quality control. This could lead to faster drug development cycles and increased competitiveness. Companies that resist adoption may face a cost disadvantage.
Integrating AI into Samsung Biologics' manufacturing processes has the potential to revolutionize workflows, leading to increased efficiency, improved quality control, and optimized resource allocation. AI could automate tasks such as process optimization, predictive maintenance, and real-time data analysis, enabling more informed decision-making.